Arvinas ARVN ARV-806 — Program-specific external expense

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

KYTXOther Program — External Research And Development Expenses Allocated By Program

$206K-63.1%

RAPPRAP219Program External Expenses — Research And Development Expense

$15.82M+98.7%

ANROALTO-203 — Direct external program expenses:

$6K-99.2%

TBPHSingle Reportable — Research And Development Expense External Related Expense

$1.95M-64.9%

SLDBExternal Research And Development Other — Other Research And Development Expense

$2.86M+3.1%

Questions, answered.

What is Arvinas's ARV-806 — program-specific external expense?

Arvinas (ARVN) reported ARV-806 — program-specific external expense of $6.5M in Q1 2026.

How has Arvinas's ARV-806 — program-specific external expense changed year-over-year?

Arvinas's ARV-806 — program-specific external expense increased by 622.2% year-over-year, from $900K to $6.5M.

What does ARV-806 — program-specific external expense mean?

This metric represents the direct, third-party costs incurred specifically for the research, development, and clinical advancement of a single drug candidate or therapeutic program. It captures outsourced expenses such as contract research organization fees, clinical trial site costs, and manufacturing services dedicated to this specific asset. Tracking these expenditures allows investors to assess the capital intensity and resource allocation priority assigned to individual pipeline programs within the company's broader R&D portfolio.